Prolgolimab

DRUG3 trials

Sponsors

St. Petersburg State Pavlov Medical University, Biocad, Blokhin's Russian Cancer Research Center

Conditions

Colorectal CancerHodgkin LymphomaUnresectable or Metastatic Melanoma

Phase 2

Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma

St. Petersburg State Pavlov Medical UniversityHodgkin Lymphoma

Start: 2023-04-19End: 2025-03-10Target: 30Updated: 2023-12-19

Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer

CompletedNCT06428487

Blokhin's Russian Cancer Research CenterColorectal Cancer

Start: 2022-03-31End: 2025-06-30Updated: 2026-04-27

Phase 3

Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma

BiocadUnresectable or Metastatic Melanoma

Start: 2022-02-01End: 2023-06-30Updated: 2023-03-24

Related Papers

Neoadjuvant Immunotherapy With Prolgolimab in Patients With Locally Advanced Microsatellite Instability/Defective Mismatch Repair Colorectal Cancer.

2025-12-10

The Role of MSI Testing Methodology and Its Heterogeneity in Predicting Colorectal Cancer Immunotherapy Response

International Journal of Molecular Sciences2025-04-052 citations

A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

Frontiers in Oncology2024-09-041 citations